Response to Sarayani et al Regarding Article, "Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque"

Circulation. 2021 Jun 22;143(25):e1033-e1034. doi: 10.1161/CIRCULATIONAHA.121.054169. Epub 2021 Jun 21.

Authors

Zsofia D Drobni^{1

2}, Thomas Mayrhofer^{1

3}, Udo Hoffmann¹, Tomas G Neilan¹

Affiliations

¹ Cardiovascular Imaging Research Center, Department of Radiology, and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston (Z.D.D., T.M., U.H., T.G.N.).
² Heart and Vascular Center, Semmelweis University, Budapest, Hungary (Z.D.D.).
³ School of Business Studies, Stralsund University of Applied Sciences, Stralsund, Germany (T.M.).

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Cardiovascular Diseases* / diagnosis
Cardiovascular Diseases* / epidemiology
Disease Progression
Humans
Immune Checkpoint Inhibitors
Plaque, Atherosclerotic*

Substances

Immune Checkpoint Inhibitors

Grants and funding